On the stock market since 2021, it operates in the world of health and science. It has 58 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 21% below its peak. The market has trimmed its expectations for the company.
Sales run at $61.9M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 31 buys and 5 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $11.75 — 57% above today’s price.
A loss of $11.4M against $61.9M in annual sales.
At the current pace of spending, the cash lasts about 2.1 years. After that, the company needs to find new money.
On our five-subject report card, DERM sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: DERM is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (57/100) says the stock isn’t cheap.